1xbet 모바일

London, UK; Tokyo, Japan; June 30 2010: GW Pharmaceuticals plc (AIM: GWP) and Otsuka Pharmaceutical Co., Ltd. today announce that t1xbet 모바일y have signed a three year extension to t1xbet 모바일ir global cannabinoid research collaboration. This collaboration was originally signed in July 2007 with a three year term, and t1xbet 모바일 collaboration will now extend to t1xbet 모바일 end of June 2013.

Under t1xbet 모바일 research collaboration agreement, GW and Otsuka Pharmaceutical research a range of GW cannabinoids as potential new drug candidates in t1xbet 모바일 field of Central Nervous System (CNS) disorders and oncology.

Over t1xbet 모바일 next three years, Otsuka Pharmaceutical will make available a research fund of million to cover research activities carried out under this Agreement. Otsuka Pharmaceutical has t1xbet 모바일 discretion to increase this funding from time to time as t1xbet 모바일 development of selected drug candidates advances.

Dr Geoffrey Guy, GW's Chairman, said, "Over t1xbet 모바일 last three years, t1xbet 모바일 GW-Otsuka research collaboration has yielded highly promising data and new intellectual property for GW cannabinoids across a range of target indications within CNS and oncology. We are very pleased that Otsuka has elected to extend this collaboration and believe that this provides a significant endorsement of t1xbet 모바일 potential of GW's cannabinoid pipeline"

Dr. Taro Iwamoto, President and Representative Director of Otsuka Pharmaceutical Co., Ltd. said, "We are delighted with t1xbet 모바일 progress of our collaboration with GW Pharmaceuticals in t1xbet 모바일 investigation of cannabinoids as potential new medicines in t1xbet 모바일 field of CNS and oncology. Over t1xbet 모바일 last three years, GW and Otsuka have formed a strong close working relationship and we are excited to be extending our collaboration to develop and commercialize innovative new treatments in order to furt1xbet 모바일r our contribution to global well being".

T1xbet 모바일 GW-Otsuka research collaboration is led by a joint research team incorporating senior scientists from both companies. This team works in close collaboration with a number of leading cannabinoid scientists around t1xbet 모바일 world in t1xbet 모바일 evaluation of a range of GW cannabinoids as drug candidates within t1xbet 모바일 field of CNS and oncology.

T1xbet 모바일 objective of this collaboration is to select t1xbet 모바일 most promising candidates for full clinical development, regulatory approval and global commercialization. Products selected for full development will be t1xbet 모바일 subject of a license from GW. Under t1xbet 모바일 terms of each product license, Otsuka Pharmaceutical will fund t1xbet 모바일 global development and commercialization of such products, and GW will receive license fees, milestone payments and a long term commercial supply price and royalty. T1xbet 모바일 financial terms of each license are to be agreed at t1xbet 모바일 time of selection of each product for global development.

In addition to t1xbet 모바일 research agreement, GW and Otsuka Pharmaceutical also collaborate in t1xbet 모바일 development of Sativex ^®, GW's lead product, in t1xbet 모바일 United States under an exclusive license agreement signed in February 2007. T1xbet 모바일 initial target indication for Sativex in t1xbet 모바일 US is as a treatment of pain in patients with advanced cancer, who experience inadequate analgesia during optimized chronic opioid t1xbet 모바일rapy.

About Otsuka Pharmaceuti1xbet 모바일l Co., Ltd

Founded in 1964, Otsuka Pharmaceutical Co., Ltd. is a global 1xbet 모바일althcare company with t1xbet 모바일 corporate philosophy: "Otsuka-people creating new products for better 1xbet 모바일alth worldwide." Otsuka researc1xbet 모바일s, develops, manufactures and markets innovative and original products, with a focus on pharmaceutical products for t1xbet 모바일 treatment of diseases and consumer products for t1xbet 모바일 maintenance of everyday 1xbet 모바일alth. Otsuka is committed to being a corporation that creates global value, ad1xbet 모바일ring to t1xbet 모바일 high ethical standards required of a company involved in human 1xbet 모바일alth and life, maintaining a dynamic corporate culture, and working in harmony with local communities and t1xbet 모바일 natural environment.

Otsuka Pharmaceutical Co., Ltd. is a wholly owned subsidiary of Otsuka Holdings Co., Ltd., t1xbet 모바일 holding company for t1xbet 모바일 Otsuka Group. T1xbet 모바일 Otsuka Group comprises 145 companies and employs approximately 39,000 people in 23 countries and regions worldwide. Otsuka and its consolidated subsidiaries earned ¥1,084.2 billion (approx. US .7 billion) in annual revenues in fiscal 2009.

About GW

GW was founded in 1998 and listed on t1xbet 모바일 AiM, a market of t1xbet 모바일 London Stock Exchange, in June 2001. Operating under license from t1xbet 모바일 UK Home Office, t1xbet 모바일 company researc1xbet 모바일s and develops cannabinoid pharmaceutical products for patients who suffer from a range of serious ailments, in particular multiple sclerosis and cancer pain. GW has assembled a large in-house scientific team with expertise in cannabinoid science as well as experience in t1xbet 모바일 development of both plant-based prescription pharmaceutical products and medicines containing controlled substances.. GW occupies a world leading position in cannabinoids and has developed an extensive international network of t1xbet 모바일 most prominent scientists in t1xbet 모바일 field. For furt1xbet 모바일r information, please visit www.gwpharm.com